Granuloma Annulare in the Setting of Secukinumab
Granuloma annulare (GA) is a common benign inflammatory skin condition classically presenting as skin-colored to erythematous dermal papules and annular plaques. Histologically, GA displays a dermal granulomatous infiltrate with palisaded histiocytes surrounding focally altered collagen. The exactly...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Dermatological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2018/5175319 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849308449341440000 |
|---|---|
| author | Matthew L. Clark Courtney A. Tobin Angela Sutton Tricia Ann Missall |
| author_facet | Matthew L. Clark Courtney A. Tobin Angela Sutton Tricia Ann Missall |
| author_sort | Matthew L. Clark |
| collection | DOAJ |
| description | Granuloma annulare (GA) is a common benign inflammatory skin condition classically presenting as skin-colored to erythematous dermal papules and annular plaques. Histologically, GA displays a dermal granulomatous infiltrate with palisaded histiocytes surrounding focally altered collagen. The exactly etiology of GA remains unknown, but it has been associated with trauma, various infections, diabetes mellitus, malignancy, thyroid disease, dyslipidemia, and several medications. In 2017, a case of GA developing in a patient treated with the interleukin 17A antagonist secukinumab was reported. Here we report a second case of GA in association with secukinumab use. |
| format | Article |
| id | doaj-art-0b1fb960ce3540f59130784eeea372f5 |
| institution | Kabale University |
| issn | 2090-6463 2090-6471 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Dermatological Medicine |
| spelling | doaj-art-0b1fb960ce3540f59130784eeea372f52025-08-20T03:54:28ZengWileyCase Reports in Dermatological Medicine2090-64632090-64712018-01-01201810.1155/2018/51753195175319Granuloma Annulare in the Setting of SecukinumabMatthew L. Clark0Courtney A. Tobin1Angela Sutton2Tricia Ann Missall3Department of Dermatology, Saint Louis University, 1755 S. Grand Blvd., Saint Louis, MO 63104, USADistinctive Dermatology, 510 Fullerton Rd., Swansea, IL 62226, USADepartment of Dermatology, Saint Louis University, 1755 S. Grand Blvd., Saint Louis, MO 63104, USADepartment of Dermatology, Saint Louis University, 1755 S. Grand Blvd., Saint Louis, MO 63104, USAGranuloma annulare (GA) is a common benign inflammatory skin condition classically presenting as skin-colored to erythematous dermal papules and annular plaques. Histologically, GA displays a dermal granulomatous infiltrate with palisaded histiocytes surrounding focally altered collagen. The exactly etiology of GA remains unknown, but it has been associated with trauma, various infections, diabetes mellitus, malignancy, thyroid disease, dyslipidemia, and several medications. In 2017, a case of GA developing in a patient treated with the interleukin 17A antagonist secukinumab was reported. Here we report a second case of GA in association with secukinumab use.http://dx.doi.org/10.1155/2018/5175319 |
| spellingShingle | Matthew L. Clark Courtney A. Tobin Angela Sutton Tricia Ann Missall Granuloma Annulare in the Setting of Secukinumab Case Reports in Dermatological Medicine |
| title | Granuloma Annulare in the Setting of Secukinumab |
| title_full | Granuloma Annulare in the Setting of Secukinumab |
| title_fullStr | Granuloma Annulare in the Setting of Secukinumab |
| title_full_unstemmed | Granuloma Annulare in the Setting of Secukinumab |
| title_short | Granuloma Annulare in the Setting of Secukinumab |
| title_sort | granuloma annulare in the setting of secukinumab |
| url | http://dx.doi.org/10.1155/2018/5175319 |
| work_keys_str_mv | AT matthewlclark granulomaannulareinthesettingofsecukinumab AT courtneyatobin granulomaannulareinthesettingofsecukinumab AT angelasutton granulomaannulareinthesettingofsecukinumab AT triciaannmissall granulomaannulareinthesettingofsecukinumab |